Key Factors
AbbVie’s remedy for patent-cliff woes is working and has the corporate on observe to return to development quickly. 
Humira continues to outperform, and the non-Humira portfolio is extra sturdy than anticipated. 
The pipeline is powerful and amplified by not too long ago introduced acquisitions anticipated to shut this yr. 
5 shares we like higher than AbbVie
AbbVie NYSE: ABBV is popping an vital nook in 2024 and is on observe to renew development. Its Humira-related patent cliff apart, the enterprise is stronger than ever, and the patent cliff is extra of a bump than a steep drop. The takeaway for traders is that Humira gross sales are resilient, docs and sufferers stay sluggish in switching to off-brand replicas, and the non-Humira portfolio is stronger than anticipated. The forecasts for gross sales of Rinvoq and Skrizi had been raised together with peak targets for up-and-comers Ubrelvy and Qlipta for migraines. 
“2024 is an thrilling yr for AbbVie, as we’re effectively positioned to completely take up Humira erosion and obtain modest operational income development, adopted by a return to sturdy development in 2025 and a excessive single-digit CAGR by the top of the last decade.”Get AbbVie alerts:Signal Up
AbbVie has a strong quarter, guides for development 
AbbVie had a strong quarter in This autumn regardless of softening Humira gross sales. The corporate reported $14.3 billion in web income for a decline of 5.4% that outpaced consensus by 190 foundation factors. The decline is due primarily to Humira gross sales, which outpaced consensus however fell 40%, dragging the Immunology portfolio down 12.3%. Weak spot was additionally seen within the Oncology phase, down 7.4%, however offset by positive factors in essential medicine and segments. 
The corporate’s key Humira replacements, Rinvoq and Skyrizi, grew by 63% and 52%, making up greater than 25% of gross sales, respectively. Neurology grew by 22% on a single-digit enhance in Botox, a 15% enhance in Ubrelvy and a 40% enhance in Vraylar gross sales. Aesthetics, together with Botox cosmetics, grew by 6.5%. 
Margin new is combined however in any other case favorable to shareholders. The GAAP and adjusted margin contracted in comparison with final yr as a result of elevated IP, RD and milestones related to acquisitions and offers. The web result’s a $0.15 headwind to the adjusted earnings that utterly offset perceived weak spot. The adjusted $2.79 is down 22.5% YOY and in need of the Marketbeat consensus by a penny. 
Steering was raised, however there’s a caveat. The corporate raised its adjusted EPS goal above the earlier vary, however the prime finish remains to be beneath the analysts’ consensus goal. The information serving to to raise share costs is the outlook for a return to development this yr and accelerating development subsequent. The corporate additionally has a strong pipeline of candidates, with a number of milestones reached within the quarter. Moreover, the steering features a $0.32 affect from the anticipated closing of acquisitions, which was confirmed within the earnings launch. Acquisitions within the oncology and neurosciences arenas complement the prevailing portfolio and strengthen its non-Humira, non-immunology enterprise. Earnings could also be weaker than anticipated immediately, however the firm is constructing leverage for long-term gross sales and margin. 
AbbVie’s capital return is secure
AbbVie is a higher-yielding inventory with a payout close to 3.7%, buying and selling at 15X earnings. The valuation is tough to pin down relative to friends; the vary is broad amongst pharma corporations, however it isn’t the very best, and AbbVie’s yield is above common. The payout is reliably secure at 50% of earnings and is predicted to develop. AbbVie has a decade of sustained will increase in its historical past and is technically a Dividend King due to its hyperlink to Abbott Laboratories. Will increase are working within the 9% vary and will proceed at a high-single-digit tempo for the subsequent few years. 
The technical outlook is bullish, however there may be resistance to beat. The inventory is up following the discharge and increasing a pattern that started in late 2023. The market is approaching an all-time excessive; it’s already at a brand new closing excessive stage and should get away to new highs quickly. As a result of the analysts have been upgrading the inventory and elevating their value targets, ABBV could maintain a rally that takes it to the $200 to $220 stage this yr. 
MarketBeat retains observe of Wall Road’s top-rated and greatest performing analysis analysts and the shares they advocate to their purchasers every day. MarketBeat has recognized the 5 shares that prime analysts are quietly whispering to their purchasers to purchase now earlier than the broader market catches on… and AbbVie wasn’t on the record.Whereas AbbVie at the moment has a “Reasonable Purchase” ranking amongst analysts, top-rated analysts consider these 5 shares are higher buys.View The 5 Shares Right here If an organization’s CEO, COO, and CFO had been all promoting shares of their inventory, would you need to know?Get This Free Report